1. Introduction {#sec1}
===============

Merkel cell carcinoma (MCC) represents a rare skin cancer associated with sun exposure affecting mainly Caucasian males over the 6th decade [@bib1], [@bib2]. Although the origin of Merkel cell has been debated, MCC is considered a Neuroendocrine tumor (NET) due to its characteristic histopathologic appearance expressing CD56, neurofilament protein (NFP), Chromogranin A, etc [@bib2], [@bib3]. However there is growing evidence in the literature of metastatic histologically-proven MCC with unidentified primary site. Neuroendocrine cancers of unknown primary account for 13% off NET\'s [@bib3] and the incidence of MCC of unknown primary has been estimated to be as high as 25% of all MCC [@bib4].

We present a case of 60 year-old patient who underwent a diagnostic biopsy of an inguinal lump at his local hospital which was proven to be an infiltrated lymph node by an MCC. Following his imaging staging with CT and PET scan, which showed only abdominal lymph node disease, he was referred to our department for surgical management.

1.1. Case presentation {#sec1.1}
----------------------

A 60 year-old man presented to his local hospital for investigation of an incidental finding of a bulge in the left inguinal area. His past medical history included hypertension and diabetes mellitus. This swelling was found to be an enlarged lymph node and the patient underwent excisional biopsy. On pathology examination, the lymph node was found to have features of a Neuroendocrine Tumor (NET), compatible with MCC. Following the results of the biopsy the patient was referred to our hospital for further management.

Upon admission to our department, clinical examination failed to reveal any skin lesions suspicious for a primary site of MCC. The screening tests for NET with NSE and Chromogranin A were negative. A Chest, Abdomen and Pelvis CT scan, revealed enlarged aortic and iliac lymph nodes. To exclude a missed primary site or other sites of metastatic disease a PET/CT was performed. The PET/CT confirmed intra-abdominal lymph node limited disease, with increased uptake at two sites; just below the left kidney with SUV max of 6.8 and at the level of the left iliac fossa with SUV max of 8.5 ([Fig. 1](#fig1){ref-type="fig"}). Also the slides from the initial lymph node biopsy were reviewed in our department where the positive immunohistochemic stainings for CK20 and synaptophysin were confirmed as well as negativity for TTF-1 staining. Given the findings of lymph node metastatic disease in the absence of a known primary MCC or other malignancy, the diagnosis of UPMCC was established.

The patient underwent an extended retroperitoneal lymph node dissection: retroperitoneally along the aorta extending ipsilaterally to the pelvis along the left external iliac vessels, up to the level of the left internal inguinal ring. At laparotomy, from cephalad to caudal the following enlarged lymph node blocks were found: (a) just above the left renal vein, (b) just below the left renal vein, (c) beside the left external iliac vein. Also a wide excision of the overlying skin of the left inguinal area including the site of the previous biopsy along with the corresponding inguinal and femoral lymph node dissection was performed ([Fig. 2](#fig2){ref-type="fig"}).

On histology, 27 lymph nodes were identified within the specimen. In detail, 2 out of 5 lymph nodes from the infrarenal block and 1 out of 8 lymph nodes from the inguinal block were found infiltrated from metastatic NET. The remaining 14 lymph nodes from other sites had no histological signs of infiltration. No evidence of a primary site was found at the excised overlying skin or subcutaneous tissue. The immunohistochemic staining for CK20, CD56, synaptophysin, Chromogranin and NSE were positive with a Ki67 of 60%, while the CK7, LCA, TTF1 and CDX-2 were negative ([Fig. 3](#fig3){ref-type="fig"}A). Also there was a high mitotic index with \>20 mitoses/HPF ([Fig. 3](#fig3){ref-type="fig"}B), confirming the diagnosis of UPMCC.

Postoperatively the patient has received 6 cycles of chemotherapy with cisplatin and etoposide, given the radical lymph node excision (R0) and minimal lymph node involvement in the specimen. He has been asymptomatic since and free of recurrence 16-months postoperatively on regular follow-up with bi-annual CT of the chest-abdomen and pelvis during the first year post adjuvant chemotherapy and annual CT scan thereafter.

2. Discussion {#sec2}
=============

MCC of unknown primary (UPMCC) remains an aggressive NET. Since the initial report of lymph node metastatic UPMCC, in 1988 [@bib5], the estimated total number of cases in the literature up to today remains less than 200 [@bib6]. It follows that UPMCC remains a rare malignancy where little is known in terms of presentation, natural course and best management approach. The diagnosis of UPMCC needs to fulfill both clinical and histologic criteria; a patient presenting with clinical lymph node positive disease without a previously diagnosed or identifiable primary tumor (MCC or NET). Furthermore on immunohistochemical staining it is necessary to express the pattern of CK20 positivity along with positivity for any of the neuroendocrine markers such as, Chromogranin A, synaptophysin or neuron specific enolase (NSE) and negative TTF-1 staining [@bib7].

The origin of MCC has been debated and both neural crest cells as well as epithelial cells have been implicated [@bib8]. Due to the rarity of this malignancy it has not yet been delineated in the case of metastatic to lymph nodes UPMCC, if the tumor arises de novo from neural cells located within the involved lymph nodes or if the primary lesion undergoes spontaneous regression [@bib3], [@bib9]. This matter remains of outmost importance as the natural history between UPMCC and MCC with a known skin primary presents significant differences. It has been shown in MCC of a known skin primary there is clear association of the carcinogenesis process with infection from polyomavirus which is on the contrary is not seen in cases of UPMCC [@bib3], [@bib10]. Furthermore, stage IIIB MCC, according to the AJCC, which corresponds to the usual presentation of extensive lymph node involvement in UPMCC, has been shown to have worst prognosis in terms of overall survival and disease free survival [@bib2], [@bib3]. It follows that these two diseases may represent different clinical entities.

Up-to-today there is no accurate and specific staging system for UPMCC [@bib3]. The most common clinical presentation of UPMCC involves an incidental finding of a lymph node enlargement, usually at the inguinal region or the axilla and it is usually discovered after excisional biopsy and pathology examination. A chest, abdomen and pelvis CT scan usually confirms lymph node involvement and reveals the extent of disease. Recently the role of PET/CT has been upgraded in depicting the sites of lymph node disease in UPMCC due to its high reported specificity and sensitivity, 98% and 90% respectively [@bib11], which was also the case with our patient. However one should keep in mind that PET/CT may upstage up to 16% of patients with UPMCC [@bib3], [@bib11].

The rarity of this tumor and the concomitant scarce reports of large series of patients with UPMCC, makes difficult to extrapolate safe conclusions about the best treatment modality. Furthermore up to today the proposed treatments have been extracted from the management of known skin primary MCC of corresponding stage, i.e. IIIB. The available options include regional surgical node dissection, and consideration of field radiation and/or chemotherapy with platinum salts and etoposide [@bib3]. In the majority of reported series some form of surgical excision (i.e. either wide local excision or formal extensive lymph node dissection), has been implemented. Some authors have advocated that extended lymph node dissection with R0 resection may offer long-term survival; there is lack of evidence supporting this statement. Interestingly there are even reports of patients who have undergone only radiotherapy or chemotherapy [@bib2], [@bib3]. The policy of our department when encountered with a UPMCC is to perform if feasible an extensive lymph node dissection of the anatomic compartment (i.e. the retroperitoneum) or of the distinct site. Our rationale is based on two facts: lymph node disease as with all malignancies, represent biologically active disease and the high reported recurrence rate after complete local resection [@bib7]. The rarity of these tumors makes almost impossible to extract good quality of evidence in the form of randomized control trials addressing this issue.

Similarly there has been no evaluation of the effect of radiotherapy or chemoradiotherapy in the adjuvant setting among patients with true UPMCC. Furthermore there are no available data on the need of adjuvant therapy when R0 resection has been achieved and in most cases adjuvant treatment is decided on case-to-case basis, depending on ill defined prognostic factors identified from known primary MCC patients [@bib12], [@bib13]. There is no consensus in the literature in regards to the best approach of adjuvant radiotherapy, chemotherapy or combination of radiochemotherapy [@bib3]. In the present case, the feeling of the department\'s Multi-Disciplinary Meeting (MDM) was that the patient should go ahead with chemotherapy only given that he presented with extensive lymph node disease (i.e. two distinct anatomic sites) and had increased Ki67 index and high mitotic index (mitoses \> 20/HPF) (i.e. aggressive behavior). Given the extended resection and the completeness of resection and the absence of extra-nodal extension, the radiotherapy was retained as a second line therapy if recurrence occurred. Interestingly, despite the absence of consensus on best available treatment, UPMCC has a better prognosis in comparison with a metastatic MCC of known primary and similar staging (i.e. IIIB) [@bib3]; this discrepancy is an argument in favor of the statement the UPMCC represents a distinct clinical entity from known primary MCC. Further investigations are needed to delineate the true natural history of this rare disease as well as the single best approach to treatment.
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![Comparative view of the PET/CT images depicting the two "hot sites" with increased uptake. A. Left paraortic block at the level of the renal vein measuring approximately 26.9 mm (white arrow) and (B) the corresponding view of the PET scan (black arrow). C. Block at the left external iliac vessels measuring 27.2 mm at the level of left internal inguinal ring (white arrow) and (D) the corresponding view of the PET scan (black arrow).](gr1){#fig1}

![Photograph of the surgical specimen aligned at it\'s anatomical continuity; 1: Suprarenal node block, 2: Infrarenal block, 3: paraortic lymph node chain extending to the iliac vessels, 3a: external iliac lymph node block, 4a: skin overlying the previous site along with the superficial inguinal lymph nodes, extending to the femoral lymph nodes (4b).](gr2){#fig2}

![A. Histological section of an inguinal lymph node, showing infiltration by a small cell carcinoma, Merkel type (black arrow). The white arrow shows residual lymphocytes. (H-E X220). B. Histological section of Merkel cell carcinoma metastatic to inguinal lymph node, showing positive Synaptophysin immunoreaction. (Immunostain X 220).](gr3){#fig3}
